|
Market Closed -
London S.E.
18:35:23 04/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,593.00 GBX | -0.75% |
|
-1.42% | +2.77% |
| 08-25 | Citigroup says 'buy' Next, UBS raises Drax | AN |
| 08-21 | Hikma Pharmaceuticals: H1 profitability beat; but needs internal biosimilars for sustained re-rating |  |
| Market Cap | 4.53B 3.9B 3.67B 3.35B 6.27B 428B 6.29B 43.34B 16.83B 219B 17.01B 16.64B 708B | P/E 2026 * |
11.7x | P/E 2027 * | 10.4x |
|---|---|---|---|---|---|
| Enterprise Value | 6.02B 5.18B 4.87B 4.45B 8.32B 568B 8.35B 57.54B 22.34B 291B 22.59B 22.09B 940B | EV / Sales 2026 * |
1.74x | EV / Sales 2027 * | 1.62x |
| Free-Float |
63.16% | Yield 2026 * |
4.01% | Yield 2027 * | 4.25% |
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| HIK | Delayed | |
CBOE
| HIK | Real-time | |
|
OTC Markets
| HKMPF | Delayed | |
|
Tradegate
| H5P | Real-time | |
|
Börse Stuttgart
| H5P | Delayed | |
|
Boerse Muenchen
| H5P | Real-time | |
|
Deutsche Boerse AG
| H5P | Delayed |
Last Transcript : Hikma Pharmaceuticals PLC
| 1 day | -0.75% | ||
| 1 week | -2.15% | ||
| Current month | -1.42% | ||
| 1 month | +1.27% | ||
| 3 months | +12.50% | ||
| 6 months | +27.75% | ||
| Current year | +2.77% |
| 1 week | 1,584.6 |  | 1,635 |
| 1 month | 1,563 | | 1,755 |
| Current year | 1,187 | | 1,762 |
| 1 year | 1,187 | | 1,865 |
| 3 years | 1,187 | | 2,360 |
| 5 years | 1,174.5 | | 2,625 |
| 10 years | 814.2 | | 2,768 |
| Manager | Title | Age | Since |
|---|---|---|---|
Said Darwazah
CEO | Chief Executive Officer | 69 | 01/12/2025 |
Areb Kurdi
DFI | Director of Finance/CFO | - | 26/02/2026 |
| Chief Tech/Sci/R&D Officer | 64 | 26/02/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 14/10/2005 | |
Khalid Nabilsi
BRD | Director/Board Member | 54 | 15/12/2025 |
Said Darwazah
CHM | Chairman | 69 | 15/05/2014 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/1/26 A | Sell | Investor Relations Manager | -26,558 | 0.0124% | ||
| 6/1/26 A | Exercice | Director | 72,763 | 0.0339% | ||
| 6/1/26 A | Exercice | Director | 20,650 | 0.0096% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.75% | -2.15% | -8.50% | -26.69% | 4.57B | |
| -0.88% | -2.27% | +55.78% | +106.31% | 1,034B | |
| -1.15% | +3.56% | +54.62% | +71.50% | 671B | |
| -1.44% | -0.65% | +21.05% | +73.05% | 460B | |
| +0.14% | -1.92% | +32.47% | +37.60% | 353B | |
| -1.33% | +3.96% | +25.71% | +45.03% | 309B | |
| -1.15% | -0.89% | -1.67% | +12.21% | 255B | |
| -1.55% | +0.05% | +54.04% | +70.32% | 240B | |
| -0.88% | +1.24% | -18.03% | -54.06% | 207B | |
| -0.15% | +1.43% | +33.64% | +96.99% | 188B | |
| Average | -0.72% | +1.00% | +24.91% | +43.23% | 372.13B | |
| Weighted average by Cap. | -0.55% | +1.04% | +37.21% | +65.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.46B 2.98B 2.8B 2.56B 4.79B 327B 4.8B 33.1B 12.85B 168B 12.99B 12.71B 541B | 3.6B 3.1B 2.91B 2.66B 4.98B 340B 5B 34.45B 13.38B 174B 13.52B 13.23B 563B |
| Net income | 412M 355M 333M 305M 570M 38.95B 572M 3.94B 1.53B 19.96B 1.55B 1.51B 64.4B | 453M 390M 367M 335M 627M 42.84B 630M 4.34B 1.68B 21.96B 1.7B 1.67B 70.83B |
| Net Debt | 1.48B 1.28B 1.2B 1.1B 2.05B 140B 2.06B 14.2B 5.51B 71.9B 5.57B 5.45B 232B | 1.31B 1.13B 1.06B 969M 1.81B 124B 1.82B 12.54B 4.87B 63.47B 4.92B 4.81B 205B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | GBX 1,593.00 | -0.75% | 365,452 |
| 03/09/26 | GBX 1,605.00 | -0.62% | 302,132 |
| 02/09/26 | GBX 1,615.00 | 0.00% | 438,713 |
| 01/09/26 | GBX 1,615.00 | -0.06% | 517,001 |
| 28/08/26 | GBX 1,616.00 | -0.74% | 444,445 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HIK Stock
Select your edition
All financial news and data tailored to specific country editions
